Nordea Investment Management AB Has $541.33 Million Stake in Becton, Dickinson and Company $BDX

Nordea Investment Management AB reduced its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 14.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,773,058 shares of the medical instruments supplier’s stock after selling 458,456 shares during the quarter. Nordea Investment Management AB owned approximately 0.97% of Becton, Dickinson and Company worth $541,329,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in BDX. Value Partners Investments Inc. boosted its stake in shares of Becton, Dickinson and Company by 18.0% during the 4th quarter. Value Partners Investments Inc. now owns 5,600 shares of the medical instruments supplier’s stock valued at $1,088,000 after buying an additional 855 shares during the period. Northside Capital Management LLC increased its stake in shares of Becton, Dickinson and Company by 0.6% in the fourth quarter. Northside Capital Management LLC now owns 53,328 shares of the medical instruments supplier’s stock worth $10,349,000 after acquiring an additional 316 shares during the last quarter. Permanent Capital Management LP purchased a new stake in shares of Becton, Dickinson and Company during the fourth quarter worth $909,000. Sagespring Wealth Partners LLC raised its holdings in shares of Becton, Dickinson and Company by 23.3% during the fourth quarter. Sagespring Wealth Partners LLC now owns 5,707 shares of the medical instruments supplier’s stock worth $1,108,000 after acquiring an additional 1,079 shares in the last quarter. Finally, Everhart Financial Group Inc. boosted its position in Becton, Dickinson and Company by 32.6% during the fourth quarter. Everhart Financial Group Inc. now owns 1,424 shares of the medical instruments supplier’s stock valued at $276,000 after purchasing an additional 350 shares during the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Bertram L. Scott sold 953 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total value of $174,027.33. Following the transaction, the director directly owned 36,763 shares in the company, valued at approximately $6,713,291.43. The trade was a 2.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Michael David Garrison sold 1,610 shares of the business’s stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $207.46, for a total value of $334,010.60. Following the transaction, the executive vice president directly owned 12,095 shares of the company’s stock, valued at $2,509,228.70. This represents a 11.75% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 2,787 shares of company stock worth $551,391. 0.40% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Royal Bank Of Canada set a $172.00 target price on Becton, Dickinson and Company in a research report on Tuesday, February 10th. JPMorgan Chase & Co. reduced their price target on Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating for the company in a report on Tuesday, February 10th. Citigroup lowered their price target on Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating for the company in a research note on Tuesday, February 10th. Morgan Stanley raised their price objective on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a research report on Tuesday, December 2nd. Finally, Zacks Research cut shares of Becton, Dickinson and Company from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 11th. Five investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $195.46.

Becton, Dickinson and Company Trading Down 1.4%

NYSE:BDX opened at $154.35 on Friday. The company’s 50 day moving average is $185.53 and its 200-day moving average is $188.82. The company has a quick ratio of 0.58, a current ratio of 1.05 and a debt-to-equity ratio of 0.67. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $187.35. The firm has a market cap of $43.95 billion, a price-to-earnings ratio of 25.18, a P/E/G ratio of 11.17 and a beta of 0.24.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.81 by $0.10. The business had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.15 billion. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. Becton, Dickinson and Company’s revenue was up 1.6% compared to the same quarter last year. During the same period last year, the business posted $3.43 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Equities analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company announced that its Board of Directors has initiated a stock repurchase program on Tuesday, January 27th that authorizes the company to repurchase $10.00 million in outstanding shares. This repurchase authorization authorizes the medical instruments supplier to buy up to 0% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s management believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 10th will be given a $1.05 dividend. This represents a $4.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 68.52%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.